Ranbaxy Laboratories, Inc.

Hovione Scientia Limited

Hovione International Limited

Banbaxy Laboratories Limited

Mohammad Salman

Naresh Kumar

Anita Chugh

Yatendra Kumar

Arturo Angel

Anita Mehta

Ram Chander Aryan

Jitendra Anant Sattigeri

Vijaya Swaminathan

Purna Chandra Ray

Pakala Kumara Savithru Sarma

Sankaranarayanan Dharmarajan

J Suresh Babu

Venkata Poornapragnacharyulu Palle

Abhijit Ray

Sunanda Ghosh Dastidar

Biswajit Das

Ashok Rattan

Sarala Balachandran

Sonali Rudra

Nidhi Gupta

Kumar Hari Bhushan

Vijay Kaul

Kirandeep Kaur

Ramnik Sharma

Jayachandra Suresh Babu

Gagan Kukreja

Vikram Krishna Ramanathan

Sujay Biswas

George Magrath

Arundutt Vishwanatham Silamkoti

Sangita Sangita

Shankar Jayram Shetty

Gowri Shankar

Bhargav R Panyda

Parma Chandra Ray

Kiran Kumar Gangakhedkar

Harish Niranjan Lal Dorwal

The invention relates to a topical suspension formulation that includes a tetracycline, a liquid medium and a polymeric gelling agent. The tetracycline may be in the form of its pharmaceutically acceptable salts, hydrates, or polymorphs and is in a suspended form within the formulation. The liquid medium is selected such that it does not dissolve or substantially minimally dissolves the tetracycline. The gelling agent is a polymeric hydrocarbon gelling agent. Preferably, the tetracycline has a particle size of less than or equal to about 20 microns.

Tetracycline topical formulations, preparation and uses thereof in treating an ocular condition

Tetracycline topical formulations, preparation and uses thereof

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Substituted pyrrole derivatives and their use as HMG-CO inhibitors

The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

Inhibitors of phosphodiesterase type-IV

Provided herein are novel substituted phenyl oxazolidinones and to processes for the synthesis thereof. Also provided are pharmaceutical compositions comprising one or more compounds described herein The compounds described can be useful antimicrobial agents, which can be effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci, as well as, anaerobic organisms, such asspp. andspp. species, and acid fast organisms, such asandspp.

Oxazolidinone derivatives as antimicrobials

This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0] hexanes, and 2,4,6-trisubstituted derivatives. The invention also relates to pharmaceutical compositions containing the compounds and the methods of treating the diseases mediated through muscarinic receptors.

Azabicyclo derivatives as muscarinic receptor antagonists

This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

The present invention relates to a cost effective and industrially advantageous process for the preparation of repaglinide.

Process for the preparation of repaglinide

The invention relates to particular hydroxyl and protected hydroxyl derivatives of compounds known to be useful as HMG CoA-reductase inhibitors. In particular, herein are provided hydroxyl and protected hydroxyl compounds of Formula I and their corresponding lactones.

HMG CoA-reductase inhibitors

The invention relates to a cost effective and industrially advantageous process for the selective methylation of a hydroxy group at the 6 position of erythromycin A derivative which comprised methylating the erythromycin A derivative with a methylating agent in a mixture of toluene and a ploar aprotic solvent.

Cost effective method for selective methylation of erythromycin A derivatives

The present invention relates to a new and industrially advantageous process for the preparation of 3-ethoxy-4-ethoxy-carbonyl-phenyl acetic acid. This compound is a key intermediate for the synthesis of Repaglinide, an oral hypoglycemic agent.

Synthesis of 3-ethoxy-4-ethoxycarbonyl phenyl acetic acid, a key acid synthon of repaglinide

The present invention relates to a process for the preparation of 13-cis isomer of Vitamin A acid, commonly known as isotretinoin, in a single step.

Process for the preparation of isotretinoin

Growing community of inventors

Haryana, India

Mohammad Salman